Effects of Vented Base Feeding Bottle in Preterm Infants With GERD Symptoms. (FeedGERD)

March 27, 2020 updated by: Francesco Cresi, MD, PhD, University of Turin, Italy

Vented Base Feeding Bottle in Preterm Infants With GERD Symptoms: Effects on Respiration-swallow Patterns and Reflux.

Aim of the study is to evaluate the effects of vented base bottles on respiration-swallow patterns and on gastroesophageal refluxes in preterm infants with clinical suspect of gastroesophageal reflux disease (GERD).

In this crossover-randomized study, we compared the effects of standard feeding bottles (A) versus vented base feeding bottles (B) on a group of patients with at least 2 clinical GERD symptoms. 24 hours of synchronized cardiorespiratory (CR) and Esophageal Multichannel intraluminal impedance (MII/pH) monitoring were evaluated for each patient. During this period, patients were fed alternatively with feeding bottle A and B.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

In preterm infants a deficit of both coordination and gastro-intestinal motility is often the underpinning cause of oxygen desaturations and gastro-esophageal reflux. Breastfeeding enhances the maturation of the respiration-swallow mechanism. For this reason, a feeding bottle that best recreates the physiological sucking from the maternal breast is highly desirable in non-breastfed newborns.

Population: newborns referred to esophageal Multichannel Intraluminal Impedance and pH-metry (MII/pH) combined with cardiorespiratory (CR) monitoring for GERD or cardio-respiratory symptoms

Materials and methods: we compare the effects of traditional feeding bottles (A) versus vented base feeding bottles (B) on cardiorespiratory and reflux events in newborns undergoing 24 hours synchronized CR and MII/pH monitoring. During the exam, newborns are fed, alternatively, by feeding bottle A and B with human milk or formula. Some training meals are offered the day before monitoring to get newborns enrolled into the study used to vented base feeding bottles.

Cardiorespiratory monitoring is performed through VitaGuard VG3100® (Getemed Medizin- und Informationstechnik AG, Teltow, Germany) based on Masimo Signal Extraction Technology (SET)® (Masimo Corp., Irvine, CA, USA). It operates with a blood oxygen saturation (SpO2) detector, placed on the right wrist, and 3 thoracic electrodes. This instrument is able to record ECG, heart rate, SpO2 and thoracic plethysmographic curve. The signals are analyzed with VitaWin 3® software (Getemed Medizin - und Informationstechnik AG, Teltow, Germany), by filtering artifacts.

The MII/pH monitoring is performed through a neonatal catheter (Infant Comfort TEC®) with 7 impedence electrodes (creating 6 impedance channels) and one pH detector able to cover the whole distance from the pharynx to the lower esophageal sphincter (LES) (channel 1). The pH detector is placed within channel 1, 1.5 cm above the LES. The correct positioning of the catheter is measured through fluoroscopy and eventually corrected. Data obtained from impedance channels that result proximal to the superior esophageal sphincter are excluded from the analysis. The acquisition and recording of MII/pH data are performed through Sleuth System, Sandhill Scientific Inc., Highlands Ranch, Colorado, USA. The analysis of MII/pH tracings is made visually by a single operator using BioView 5.3.4 software (Sleuth System, Sandhill Scientific Inc., Highlands Ranch, Colorado, USA).

The variables analyzed are listed as follows:

Clinical variables:

  • feeding time (min)
  • feeding total volume (mL)
  • n. GER during feeding
  • n. GER in the post-prandial period (150 min after feeding)

Cardiorespiratory variables:

  • frequency of apnea, desaturation and bradycardia during feeding
  • frequency of apnea, desaturation and bradycardia during post-prandial period
  • mean duration of apnea during feeding and post-prandial period
  • mean and minimum desaturation level during feeding and post-prandial period
  • mean and minimum heart rate during feeding and post-prandial period

MII/pH variables:

  • Swallow frequency during feeding and post-prandial period (events/h)
  • Bolus Presence Time (BPT): seconds between bolus entry and bolus exit in the distal channel
  • Bolus Head Advancing Time (BHAT): seconds between bolus entry in proximal channel and entry in distal channel
  • Bolus Head Advancing Time Corrected for Esophageal Length (BHATc): BHAT corrected for esophageal length (BHATc = BHAT / esophageal length)
  • Reflux pH: minimum pH value registered during each GER event. It classifies refluxes into 3 different types: acid (pH < 4), weakly acid (pH 4-7) and weakly alkaline (pH > 7)
  • GER frequency, (events/h)
  • Bolus Clearance Time (BCT): reflux duration, recorded at distal channel (s)
  • Bolus Reflux Extent (BRE), (n. channels)
  • Proximal GER frequency (events/h)
  • Bolus Exposure Index (BEI): percentage of time in which GER involves esophagus during MII/pH monitoring
  • Reflux Index (RI): percentage of time during which pH falls below 4 during MII/pH monitoring

Randomization: the alternate use of feeding bottles A and B is set by a binary random sequencing generated by Microsoft Office Excel software that indicates the first feeding bottle to be used. This is a single-blind study since the sequence is unknown to the specialist in charge of reporting MII/pH and CR monitoring.

Statistical analysis:

The analysis is made with Statistical Software Package For Windows® (StatSoft, Inc., Tulsa, Oklahoma, USA). Kolmogorov-Smirnov test and exploratory data analysis are used to define normality range. Data will be expressed as mean and standard deviation (SD), or as median and interquartile range if more appropriate. Differences among cardiorespiratory and MII/pH variables will be evaluated with Student paired T test or Wilcoxon test if more appropriate. Significance will be considered as p<0.05.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • (to)
      • Torino, (to), Italy, 10126
        • Ospedale S.Anna di Torino

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 week to 3 months (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • weight ≥ 1500 g at the time of examination
  • at least 2 GERD symptoms
  • exclusive enteral feeding
  • parents' informed consent

Exclusion Criteria:

  • congenital abnormalities
  • perinatal asphyxia
  • respiratory, genetic, metabolic, infectious and/or neurologic disease
  • pharmacological therapies, in the last 7 days, able to affect esophageal motility

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Start feeding with Device A, "standard"
Alternatively feeding with standard feeding bottle (Device A) and vented base feeding bottle (Device B)
standard bottle
vented base bottle
Experimental: Start feeding with Device B, "vented"
Alternatively feeding with vented base feeding bottle (Device B) and standard feeding bottle (Device A)
standard bottle
vented base bottle

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Frequency of cardiorespiratory events (feeding+postprandial time)
Time Frame: calculated throughout 24 hour

Cardiorespiratory events / hour

  • apnea (no breathing movement for at least 20 s, or less if associated with desaturation/bradycardia)
  • desaturation (SpO2 <80%)
  • bradycardia (heart rate < 80 bpm for at least 1 s)
calculated throughout 24 hour

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Swallow event characteristics (feeding time)
Time Frame: calculated throughout 30 minute interval after the beginning of the milk meal
Swallow event is identified as a rapid increase in impedance preceded by a drop in impedance to 50% of baseline beginning in the proximal channel and proceeding in an anterograde direction to the most distal channel, followed by the recovery of baseline values at each channel
calculated throughout 30 minute interval after the beginning of the milk meal
Frequency of reflux events (postprandial time)
Time Frame: calculated throughout 150 minute interval after the end of the milk meal
Reflux event is defined as: a drop of impedance to 50% of the basal value for at least 5 s, starting in the most distal channel and proceeding to one or more proximal channels and followed by a recovery of the impedance baseline values
calculated throughout 150 minute interval after the end of the milk meal

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Francesco Cresi, MD PhD, University of Turin, Italy

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2017

Primary Completion (Actual)

December 1, 2018

Study Completion (Actual)

December 1, 2018

Study Registration Dates

First Submitted

January 12, 2017

First Submitted That Met QC Criteria

January 21, 2017

First Posted (Estimate)

January 25, 2017

Study Record Updates

Last Update Posted (Actual)

March 31, 2020

Last Update Submitted That Met QC Criteria

March 27, 2020

Last Verified

March 1, 2020

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on GERD

Clinical Trials on A

3
Subscribe